

Cover Story
Guest Editorial
By John H. Stewart and Robert A. Winn
Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.
By Claire Dietz and Matthew Bin Han Ong
In Brief
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Did peer review fail? Nature Medicine’s chronotherapy paper retraction raises questions
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m. - OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill
- Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds















